egnite, Inc. expands technology to improve the quality of care for heart failure patients
New data from egnite demonstrates opportunity to improve survival and reduce readmission rates for heart failure patients...
Read MoreNew data from egnite demonstrates opportunity to improve survival and reduce readmission rates for heart failure patients...
Read MoreBACKGROUND Progression from moderate to severe aortic stenosis (AS) warrants careful monitoring due to the increased risk of sudden death and heart failure, with disease progression significantly varying among patients and no accurate predictive tools presently available. OBJECTIVE A Disease Progression Algorithm was developed from a deidentified database of 1,163,923 echocardiographic (echo) reports from 35 […]
Read MoreOctane’s annual High Tech Awards celebrates and recognizes individuals and companies who make Orange County a center of medical technology innovation.
Read MoreWe’re all familiar in clinical practice with many patients who, at least on first glance, look the same. If you look at the output of the echo report and database, two patients appear to fall under the moderate AS category but may have been undiagnosed with severe AS. The CardioCare platform...
Read MoreCongestive heart failure (CHF) results in poor patient outcomes and increases the cost of care particularly with recurrent CHF hospitalizations. Using the CardioCare platform...
Read MoreThe CardioCare platform allows us to look at referral patterns for our structural heart patients by pathology. Actionable insights from CardioCare powered an educational program...
Read More© 2024 egnite, Inc. All Rights Reserved. egnite, egnite Inc., CardioCare, the heart logo, and the spark logo are trademarks of egnite, Inc. All other trademarks are property of their respective owners.
Privacy Policy Intellectual Property Terms of Use Implementation Kit Careers